Maysam Pessian is an associate in the Century City office of Wilson Sonsini Goodrich & Rosati. His practice focuses on patent prosecution and intellectual property counseling, serving clients in a wide range of technology fields, including the pharmaceuticals and biotechnology industries.
During law school, Maysam was an extern for licensing officers in the Invention Transfer Group at UC Irvine Applied Innovation. In this role, he performed a wide range of tasks, including preparing patentability and marketability reports on UC Irvine-owned technology; preparing targeted research reports on various private companies as a part of campus outreach efforts for collaboration; and drafting term sheets for technology licensing agreements and inter-institutional agreements. In addition, Maysam worked at the Domestic Violence Clinic at UC Irvine, where he represented victims of domestic violence in various proceedings and hearings to obtain temporary restraining orders, favorable financial terms, and permanent restraining orders in California Family Court.
Before embarking on his legal career, Maysam acquired extensive experience in immunology and neurobiology. Previously, he worked at an early-stage research company, where his work focused on various cancer vaccines and immunotherapies—specifically vaccina virus-derived oncolytic virus combination therapies. During graduate school, his research focused on the remodeling of the nervous system and functional recovery after spinal cord injury—specifically the effects of modulating Wnt-Ryk signaling. As an undergraduate, Maysam volunteered at the UC San Diego Moores Cancer Center as a research assistant in Boris Minev's laboratory, where he researched nanoparticle-delivered cancer vaccines.
Maysam Pessian is an associate in the Century City office of Wilson Sonsini Goodrich & Rosati. His practice focuses on patent prosecution and intellectual property counseling, serving clients in a wide range of technology fields, including the pharmaceuticals and biotechnology industries.
During law school, Maysam was an extern for licensing officers in the Invention Transfer Group at UC Irvine Applied Innovation. In this role, he performed a wide range of tasks, including preparing patentability and marketability reports on UC Irvine-owned technology; preparing targeted research reports on various private companies as a part of campus outreach efforts for collaboration; and drafting term sheets for technology licensing agreements and inter-institutional agreements. In addition, Maysam worked at the Domestic Violence Clinic at UC Irvine, where he represented victims of domestic violence in various proceedings and hearings to obtain temporary restraining orders, favorable financial terms, and permanent restraining orders in California Family Court.
Before embarking on his legal career, Maysam acquired extensive experience in immunology and neurobiology. Previously, he worked at an early-stage research company, where his work focused on various cancer vaccines and immunotherapies—specifically vaccina virus-derived oncolytic virus combination therapies. During graduate school, his research focused on the remodeling of the nervous system and functional recovery after spinal cord injury—specifically the effects of modulating Wnt-Ryk signaling. As an undergraduate, Maysam volunteered at the UC San Diego Moores Cancer Center as a research assistant in Boris Minev's laboratory, where he researched nanoparticle-delivered cancer vaccines.
- J.D., University of California, Irvine School of Law, 2018Member, Domestic Violence Clinic; Finalist, Tech Surge competition; Finalist, Beall Center New Venture competition
- M.S., Biology, University of California, San Diego, 2013Thesis: Blocking Wnt Signaling in the Corticospinal Tract and Proprioceptive Sensory Axons; Teaching Assistant, Brain and Behavioral Development
- B.S., Biology, University of California, San Diego, 2012Minor in Humanities
- State Bar of California
- U.S. Patent and Trademark Office
- J.D., University of California, Irvine School of Law, 2018Member, Domestic Violence Clinic; Finalist, Tech Surge competition; Finalist, Beall Center New Venture competition
- M.S., Biology, University of California, San Diego, 2013Thesis: Blocking Wnt Signaling in the Corticospinal Tract and Proprioceptive Sensory Axons; Teaching Assistant, Brain and Behavioral Development
- B.S., Biology, University of California, San Diego, 2012Minor in Humanities
- State Bar of California
- U.S. Patent and Trademark Office
Select Publications
- Co-author with J. Siegel, M. Arnold, A. Johnson, M. Li, S. Pennebaker, B. Tamsut, A. Zeng, and J. Zhang, "Rights holders need to keep faith in standard-essential patents," IAM Magazine, June 2016
- Co-author with E. Hollis, N. Ishiko, and Y. Zou, "Ryk controls remapping of motor cortex during functional recovery after spinal cord injury," 19(5) Nature Neuroscience 697-705, 2016
- Co-author with M. Kilinc, K. Ehrig, and A. Szalay, "Colonization of xenograft tumors by oncolytic vaccinia virus (VACV) results in enhanced tumor killing due to the involvement of myeloid cells," 14(1) Journal of Translational Medicine 340, 2016
- Co-author with E. Hollis, N. Ishiko, and Y. Zou, "Remodelling of spared proprioceptive circuit involving a small number of neurons supports functional recovery," 6 Nature Communications 6079, 2015
- Co-author with B. Minev, M. Kilinc, and A. Szalay, "Combination Immunotherapy of Advanced Lymphoma with Oncolytic Vaccinia Virus and Checkpoint Inhibitor Following Local Tumor Irradiation," 124(21) Blood 4487, 2014
- Co-author with B. Minev, M. Kilinc, and A. Szalay, "Combination immunotherapy of advanced lymphoma with oncolytic vaccinia virus and checkpoint inhibitor following tumor irradiation," 2 (Suppl 3) The Journal of ImmunoTherapy of Cancer P122, 2014
- Co-author with N. Chen, M. Kilinc, and A. Szalay, "Targeting hematologic malignancies with oncolytic vaccinia virus constructs," 1 (Suppl 1) The Journal of ImmunoTherapy of Cancer P226, 2013
Select Speaking Engagements
- “When Do You File a Patent Application?” University Lab Partners, March 11, 2021
- "How Do Others’ Patents Affect YOU? Patentability vs. Freedom-to-Operate,” University Lab Partners, July 16, 2020
Select Publications
- Co-author with J. Siegel, M. Arnold, A. Johnson, M. Li, S. Pennebaker, B. Tamsut, A. Zeng, and J. Zhang, "Rights holders need to keep faith in standard-essential patents," IAM Magazine, June 2016
- Co-author with E. Hollis, N. Ishiko, and Y. Zou, "Ryk controls remapping of motor cortex during functional recovery after spinal cord injury," 19(5) Nature Neuroscience 697-705, 2016
- Co-author with M. Kilinc, K. Ehrig, and A. Szalay, "Colonization of xenograft tumors by oncolytic vaccinia virus (VACV) results in enhanced tumor killing due to the involvement of myeloid cells," 14(1) Journal of Translational Medicine 340, 2016
- Co-author with E. Hollis, N. Ishiko, and Y. Zou, "Remodelling of spared proprioceptive circuit involving a small number of neurons supports functional recovery," 6 Nature Communications 6079, 2015
- Co-author with B. Minev, M. Kilinc, and A. Szalay, "Combination Immunotherapy of Advanced Lymphoma with Oncolytic Vaccinia Virus and Checkpoint Inhibitor Following Local Tumor Irradiation," 124(21) Blood 4487, 2014
- Co-author with B. Minev, M. Kilinc, and A. Szalay, "Combination immunotherapy of advanced lymphoma with oncolytic vaccinia virus and checkpoint inhibitor following tumor irradiation," 2 (Suppl 3) The Journal of ImmunoTherapy of Cancer P122, 2014
- Co-author with N. Chen, M. Kilinc, and A. Szalay, "Targeting hematologic malignancies with oncolytic vaccinia virus constructs," 1 (Suppl 1) The Journal of ImmunoTherapy of Cancer P226, 2013
Select Speaking Engagements
- “When Do You File a Patent Application?” University Lab Partners, March 11, 2021
- "How Do Others’ Patents Affect YOU? Patentability vs. Freedom-to-Operate,” University Lab Partners, July 16, 2020
Biological Sciences and Biotechnology
- Antigen presentation
- Biochemical assays
- Biologics
- Cancer biology
- Cancer therapeutics
- CAR-T cells
- Cell biology
- Cell culture products
- Cell therapy
- Cellular biology
- Cellular immunology
- Epigenetics
- Genetics
- Genomics
- Immuno-oncology
- Immunobiology
- Immunology
- MicroRNA (miRNA) research
- Molecular biology
- Molecular genetics
- Neurobiology
- Stem cell biology
- T and B cell biology
- T cell biology
- T cell immunology
Biological Sciences and Biotechnology
- Antigen presentation
- Biochemical assays
- Biologics
- Cancer biology
- Cancer therapeutics
- CAR-T cells
- Cell biology
- Cell culture products
- Cell therapy
- Cellular biology
- Cellular immunology
- Epigenetics
- Genetics
- Genomics
- Immuno-oncology
- Immunobiology
- Immunology
- MicroRNA (miRNA) research
- Molecular biology
- Molecular genetics
- Neurobiology
- Stem cell biology
- T and B cell biology
- T cell biology
- T cell immunology
The funding allows LuxWall to scale up production at its newly opened factory in Litchfield, Michigan, which received the support from Michigan Governor Gretchen Whitmer. It will also enable the construction and expansion of a second factory in Detroit, Michigan, as well as the growth of research and development at the R&D Center in Ypsilanti, Michigan.
The Wilson Sonsini team that advised LuxWall on the transaction includes Matt Bresnahan, Maysam Pessian, and Jane Yang.
For more information, please see LuxWall’s news release.
- Privacy Policy
- Terms of Use
- Accessibility